BAL (B-aggressive lymphoma) is a novel risk-related gene that is expressed at significantly higher levels in fatal high-risk diffuse large B-cell lymphomas (DLB-CL) than in cured low-risk tumors. The major BAL cDNA encodes a 88 kDa nuclear protein. BAL-overexpressing B-cell lymphoma transfectants have significantly higher rates of migration than vector-only transfectants, indicating that the risk-related BAL gene promotes malignant B-cell migration.

Reactivity has been confirmed in with human Farage non-Hodgkin′s B-cell lymphoma and human BC-1 B-lymphocyte lymphoma lysates.

Recognizes BAL.

Synthetic peptide derived from the C-terminal region of the short isoform of human BAL protein (B-aggressive lymphoma, poly (ADP-ribose) polymerase family member 9, PARP9).

Anti-BAL Antibody is an antibody against BAL for use in IP & WB.

Research Category
Apoptosis & Cancer

Epigenetics & Nuclear Function

Research Sub Category
Tumor Markers

Transcription Factors

Western blotting: 1-3 μg/mL
Immunoprecipitation: 7 μg/ reaction

Format: Purified

ImmunoAffinity Purified

This polyclonal antibody is supplied in 400 μL of phosphate buffered saline (pH 7.4) containing 0.1% sodium azide.

Store at -20°C in undiluted aliquots for 1 year from date of shipment.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.